Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyDaniel R. Gomez, John V. Heymach, Chad Tang et al.|Journal of Clinical Oncology|2019Cited by 1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R. Gomez, John V. Heymach, George R. Blumenschein et al.|The Lancet Oncology|2016Cited by 1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus documentYolande Lievens, Wendy A. Woodward, Matthias Gückenberger et al.|Radiotherapy and Oncology|2020Cited by 646
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung CancerA. Ashworth, George Rodrigues, Suresh Senan et al.|Clinical Lung Cancer|2014Cited by 437
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancerEverett J. Moding, Maximilian Diehn, Yufei Liu et al.|Nature Cancer|2020Cited by 369